InGOG240,theexperimentalarmshavebeendesignedto answertwocriticalquestions.Thefirstisachemotherapyquestionandwhetherthenon-platinumdoublettopotecanpluspaclitaxelwouldhavegreateractivityintherecurrentsettinggiven theincreasedusageofplatinum-basedchemoradiationupfront for locally advanced cancers. For these two case reports, the inclusionofbiologicsbyTakano'steamwasabrilliantstroke. Importantly,thesecondquestiontobeaddressedbyGOG240 iswhethertargetedtherapyhasaroleinthispopulation.
Signal transduction pathways governed by the epidermal growth factor receptor (EGFR) and those involved in angiogenesis have been the subject of recent investigations. AtASCO2009,Movvaetal. [9] havereportedonEGFRimmunostaining in 80 patients with cervical cancer. Although the investigators did not detect any correlations between EGFR expression and clinical parameters (including overall survival(OS)),EGFRinhibitorsoftheextracellulardomain (e.g. cetuximab) may be expected to be useful for the treatmentofcervicalcancersthatoverexpressthisreceptor.Randall et al. [10] have recently shown that tumor angiogenesis asmeasuredbyCD31microvesseldensityisanindependent prognosticfactorforbothprogressionfreesurvival(PFS)and OSinhigh-risk,early-stagecervicalcancer.Inthesettingof metastaticand/orrecurrentdisease,Monketal. [11] conductedarandomizedphaseIIstudycomparingtheoraltyrosine kinaseinhibitorspazopanibandlapatinib.Pazopanibisantiangiogenicandtargetsthevascularendothelialgrowthfactor (VEGF) and the platelet-derived growth factor receptors, whilelapatinibtargetsEGFRandHER2.Inthisstudyof235 patients,bothPFSandOSweresignificantlyprolongedwith theanti-vascularagentpazopanibcomparedtolapatinib.
AsmallcaseseriesbyWrightetal. [12] describedthesuccessfulcombinationofbevacizumabwithcytotoxicagentsin therecurrentandmetastaticsettingamongpreviouslyirradiated patients. Importantly, the antiangiogenesis agent bevacizumab in combination with chemotherapy has been FDAapproved for locally advanced and recurrent breast cancer, InthisissueofOnkOlOgieTakanoetal. [1] reportcompleteremissionsintwopatientswithmetastaticandrecurrentcervical cancer. Prior to recurrence, one patient had received chemoradiationforlocallyadvanceddisease,andtheotherhadbeen treated with adjuvant pelvic radiation following hysterectomy. Importantly, both of these patients were treated with weekly paclitaxel(80mg/m 2 )pluscarboplatin(AUC2.0)(days1, 8, 15) andweeklybevacizumab(days1, 8, 15, 21) .Casereportsrarely warranteditorials,butthesearenoteworthybecausetheactivity andtolerabilityoftheantivascularagentbevacizumabincombinationwithcytotoxictherapyformetastaticandrecurrentcervicalcanceristhesubjectoftheongoingphaseIII,randomized trialoftheGynecologicOncologyGroup(GOG240) [2] .
Thelandscapehaschangedovertheyears.Duetosuccessful screening programs with Papanicoloau testing (with and withouthigh-riskHPVtriage/co-primaryscreeninginwomen over 30), incidence and mortality rates of cervical cancer in the United States and Western European nations have dramatically decreased. In addition, concurrent platinum-based chemoradiation has become the standard of care for locally advanced disease [3] . Many recurrent tumors may therefore beplatinumresistant.
TheGOGhascompletednofewerthan8multi-centerphase IIIrandomizedtrialstostudyplatinum-basedtherapiesforrecurrentand/ormetastaticdisease [4, 5] .Themostrecentlycompletedstudy,GOG204,compared4platinum-baseddoublets using paclitaxel, topotecan, gemcitabine, and vinorelbine [6] . None of the experimental arms out-performed the reference arm.Forthisreason,cisplatinpluspaclitaxelhasbeenselected asthecontrolarmforGOG240whichwasactivatedinApril 2009andisoneof3ongoingphaseIIItrialsbeingconducted throughout the world for this patient population.
The Japan Clinical Oncology Group (JCOG) is currently enrolling patientsontoatrialcomparingcisplatinpluspaclitaxelvs.carboplatinpluspaclitaxel( fig.1) [7] .Thenon-platinumdoublet,topotecanpluspaclitaxelisbeingstudiedbytheArbeitsgemeinschaftGynäkologischeOnkologie(AGO)( fig.2) [8] .
BeyondPlatinumforMetastaticandRecurrent CarcinomaoftheCervix 553 firstandsecondlinetherapyformetastaticcolorectalcancer, untreatednon-smallcelllungcancer(NSCLC),andglioblastomamultiforme.Thedrugiscurrentlybeingstudiedbythe GOG in primary advanced and platinum-sensitive recurrent ovariancarcinoma,aswellasinuterineendometrialcancers andcarcinosarcomas.AphaseIIevaluationofbevacizumab at15mg/kgq21dayswasundertakenwithintheGOG(protocol227C) [13] .The26%riskreduction(RR)ofbevacizumab among previously irradiated patients was among the highest RRsnotedwithintheGOG'sphaseIIexperienceforrecurrent cervical cancer, and the prolongation in PFS was also impressive. These data strongly support the addition of bevacizumab to the therapeutic regimens employed in the two patientsreportedbyTakanoetal. [1] . GiventhepotentialsharedtumorbiologybetweenNSCLC and cervical cancer along with the activity of platinum plus paclitaxelwithbevacizumabinNSCLC [14] ,aplatinum-based regimenwhichincludesbevacizumabwasselectedtobeone of the experimental arms in GOG 240. Assuming no interaction between the non-platinum doublet and bevacizumab, a 2×2 factorial design has been selected to answer both the chemotherapy question and the biologic/antivascular question.TheschemaforGOG240appearsinfigure3.
Perhaps a second important contribution of Takano's paper is that we are seeing increasing evidence that therapy formetastaticcervicalcarcinomadoesnotneedtobesolely palliative.In2007,Quietal. [15] reportedonlong-termsurvivorswhopresentedwithsupraclavicularmetastases.Although bothpatientsinthepresentreporthavenothadextendedfollow-up,itisnonethelessexcitingthatbothhadbeentreated withmeasureablediseaseandexperiencedcompleteresponses to cytoxotic and antivascular therapy. Notwithstanding significant unanticipated toxicities, the ongoing trials of the AGO,JCOG,andGOGhavebeenpositionedtofurtherrefinetherapeuticoptionsforthisdisease. Overall survival (OS) Frequency and severity of toxicity
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